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Abstract: Many models of diabetic nephropathy have been reported.  However, it is rare that 
the characteristic findings of severe human diabetic nephropathy, such as diffuse, nodular, 
and exudative lesions, are all detected in one model mouse.  Previously, we reported that 
MAFA-deficient and beta cell-specific MAFK-overexpressing hybrid transgenic (Mafa–/–Mafk+) 
mice develop diabetes mellitus and, after uninephrectomy, demonstrate these characteristic 
lesions.  In this study, we administered TCV-116 (candesartan cilexetil) to Mafa–/–Mafk+ mice 
after uninephrectomy and examined whether TCV-116 ameliorated the diabetic nephropathy.  
We also evaluated the utility of these mice as a model for developing treatments for diabetic 
nephropathy.  We performed uninephrectomy of the Mafa–/–Mafk+ mice at 8 weeks old.  We 
then divided these mice into two groups as follows: 1) an untreated group and 2) a group 
treated with TCV-116 at 5 µg/g/day from 10 to 20 weeks.  TCV-116 treatment did not affect 
serum glucose levels.  However, in the treated group, urinary protein excretion, mesangial 
matrix expansion, enlargement of the kidney, and glomerular surface area were all improved 
relative to untreated mice.  Oxidative stress is known to be increased in diabetic nephropathy 
and to be suppressed by TCV-116.  The urinary level of 8-OHdG, an oxidative stress marker, 
at 20 weeks was lower in the TCV-116-treated group than in the untreated group.  From these 
results, we concluded that the Mafa–/–Mafk+ mouse is a useful model to analyze diabetic 
nephropathy and a useful tool for the development of new drugs to treat diabetic 
nephropathy.
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Introduction
Diabetic nephropathy is a major complication of dia-
betes mellitus and is also the leading cause of end-stage 
renal disease [7].  Mouse models of diabetes mellitus are 
essential experimental tools for investigating the mech-
anisms by which diabetic nephropathy develops.  A 
variety of mouse models of diabetic nephropathy have 
been reported, such as streptozotocin-induced mice [15], 
Akita mice [16], NOD mice [32], ob/ob mice [31], and 
db/db mice [26].  However, the major deficiency in ani-
mal models of diabetic nephropathy is the absence of 
severe human-like diabetic histopathological findings 
[4].  Previously, we have reported that MAFA [v-maf 
musculoaponeurotic fibrosarcoma oncogene family, pro-
tein A (avian)]-deficient and beta cell-specific MAFK 
[v-maf musculoaponeurotic fibrosarcoma oncogene fam-
ily, protein K (avian)]-overexpressing hybrid transgenic 
(Mafa–/–Mafk+) mice [27] develop diabetes mellitus at a 
young age, and after uninephrectomy, these mice dem-
onstrate three characteristics of human diabetic neph-
ropathy: namely, diffuse, nodular, and exudative lesions. 
Mafa–/–Mafk+ mice are expected to be a useful tool for 
analyzing the development and treatment of diabetic 
nephropathy.
MAFA is a member of the large Maf family of tran-
scription factors [2].  The Mafa gene is expressed in 
pancreatic beta cells, and its level of expression and the 
DNA binding activity of the resulting MAFA protein 
depend on the serum glucose concentration [10, 11].  We 
generated MAFA-deficient mice and determined that 
MAFA is a key regulator of glucose-stimulated insulin 
secretion, insulin transcription, and the maintenance of 
pancreatic islet structure in vivo [35].  MAFB and c-MAF 
are the two other members of the large Maf family, and 
they are also expressed in pancreatic beta cells [10, 12, 
17, 21].  These transcription factors might activate the 
expression of the insulin gene.  MAFK is a small Maf 
transcription factor and acts as a dominant negative pro-
tein to suppress the effect of the large Maf proteins [9]. 
In Mafa–/–Mafk+ mice, the MAFA protein is absent, and 
the transcriptional activity of the other large Maf proteins 
is repressed in beta cells, which leads to the development 
of overt severe diabetes mellitus [27, 28].
The major therapeutic approaches that have been in-
vestigated for diabetic nephropathy include intensive 
glycemic control, restriction of dietary protein, and an-
tihypertensive treatment involving inhibition of the renin 
angiotensin system (RAS) [23].  Many pathophysiolog-
ical, genetic, and inflammatory issues in diabetic neph-
ropathy have been reported to be related to RAS.  There 
have been many reports that the inhibition of RAS with 
inhibitors of angiotensin converting enzyme or blockers 
of the angiotensin II receptor suppresses the progress of 
albuminuria and/or proteinuria in both experimental and 
clinical diabetic nephropathy [3, 7, 24].
In this study, we administered the angiotensin II recep-
tor blocker TCV-116 (candesartan cilexetil) to Mafa–/–
Mafk+ mice after uninephrectomy and examined wheth-
er TCV-116 ameliorated diabetic nephropathy in these 
mice.  We also evaluated the utility of these mice as a 




We generated Mafa–/–Mafk+ mice as described previ-
ously [27].  All mice used had the ICR genetic back-
ground and were 8-week-old males.  We performed 
uninephrectomy of the Mafa–/–Mafk+ mice at 8 weeks 
old (W) by ablating the left renal artery and ureter. 
Mafa+/+ mice were used as wild-type (WT) mice (n=6). 
WT mice that had not undergone uninephrectomy were 
used as controls.  Mice were fed a normal diet that com-
prised a commercial laboratory chow (MF, Oriental Yeast 
Co., Ltd., Tokyo, Japan) and were maintained under 
specific pathogen-free conditions in the Laboratory 
Animal Resource Center of the University of Tsukuba. 
All experiments were performed in accordance with the 
Guide for the Care and Use of Laboratory Animals at 
the University of Tsukuba, and the study was approved 
by the Institutional Review Board of the university.
Drug
The angiotensin II type 1 receptor antagonist, TCV-
116, was synthesized by Takeda Chemical Industries, 
Ltd. (Osaka, Japan).  After uninephrectomy, the Mafa–/–
Mafk+ mice were divided into two groups as follows: the 
AK group (n=6), which received no treatment, and the 
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TAK group (n=6), which was treated with TCV-116.  The 
TAK group received TCV-116 (5 µg/kg/day) given in 
drinking water from 10 to 20 weeks of age.  Owing to 
the fact that the Mafa–/–Mafk+ mice developed hyperg-
lycemia, these mice showed polyuria and drank substan-
tially more than 10 ml of water/day.  The TCV-116 (5 
µg/kg/day) was administered in 5 ml of drinking water 
every day.  After the mice had emptied the drink bottle, 
we refilled it with fresh water that did not contain TCV-
116.  By this approach, we could be sure that the mice 
received the exact dose of TCV-116.  Vehicle, which 
comprised ethanol (0.1%, v/v), polyethylene glycol 
(0.1%, v/v), and sodium bicarbonate (5 mmol/l), was 
added to the TCV-116 to increase its solubility in water. 
The WT mice (n=6) did not receive TCV-116.
Analysis of urinary protein excretion, urinary excretion 
of creatinine, and renal serological assays
The urine of each mouse was collected over a 24-h 
period during housing in an individual metabolic cage. 
The amount of proteinuria was assessed by measuring 
the turbidity of the urine upon the addition of 3% sul-
phosalicylic acid.  The urinary excretion of creatinine 
was measured using a LabAssayTM Creatinine kit (Wako, 
Osaka, Japan).  Blood samples were collected from the 
tail vein of the mice.  The concentrations of serum crea-
tinine and fed glucose were measured using a DRI-
CHEM 3500 automated analyzer for routine laboratory 
tests (Fujifilm Corporation, Tokyo, Japan).
Measurement of systolic blood pressure
Systolic blood pressure (SBP) was measured with a 
noninvasive tail cuff and pulse transducer system (BP-
98A; Softron, Tokyo, Japan).
Histopathological analysis
Kidney tissues were fixed with 10% formalin and 
embedded in paraffin.  Sections were stained with peri-
odic acid-Schiff (PAS) and Masson’s trichrome (MT). 
For histological analysis, the glomerular surface area of 
30 glomeruli in each kidney section was measured using 
a BIOREVO BZ-9000 fluorescence microscope (Key-
ence, Osaka, Japan), and the mean glomerular surface 
area was determined.
Measurement of urinary levels of 8-hydroxy-2-
deoxyguanosine
The urinary excretion of 8-hydroxy-2-deoxyguanosine 
(8-OHdG) was measured by competitive enzyme-linked 
immunosorbent assay using a commercially available 
kit, New 8-OHdG Check (Japan Institute for the Control 
of Aging, Shizuoka, Japan).
Statistical analysis
All data are expressed as means ± SEM.  Multiple data 
comparisons were performed by using one-way analysis 
of variance (ANOVA) with post hoc analysis (StatView 
5.0, SAS Institute Inc., Cary, NC, USA).  P values <0.05 
were considered statistically significant.
Results
Effects on serum glucose, body weight, and blood 
pressure
The mean serum glucose levels of the AK and TAK 
mice were significantly higher than those of the WT mice 
throughout the observation period [1151.6 ± 47.2 mg/dl 
(10 W) and 1320.0 ± 113.4 mg/dl (20 W) for AK mice; 
1124.5 ± 65.0 mg/dl (10 W) and 1369.8 ± 35.4 mg/dl 
(20 W) for TAK mice; 173.0 ± 8.2 mg/dl (10 W) and 
159.8 ± 38.3 mg/dl (20 W) for WT mice; Fig. 1A].  There 
was no significant difference in mean body weight be-
tween the AK and TAK mice.  However, the mean body 
weights of the AK and TAK mice were significantly 
lower than those of the WT mice [24.4 ± 1.2 g (10 W) 
and 27.4 ± 1.5 g (20 W) for AK mice; 27.1 ± 1.0 g (10 
W) and 29.6 ± 1.7 g (20 W) for TAK mice; 35.4 ± 1.0 g 
(10 W) and 41.2 ± 1.9 g (20 W) for WT mice; Fig. 1B]. 
Systolic blood pressure in the TAK mice tended to de-
crease after TCV-116 treatment but was not significant-
ly lower than that of the AK mice at 20W (119.5 ± 3.8 
mmHg (10 W) and 115.4 ± 9.4 mmHg (20 W) for AK 
mice; 118.6 ± 4.5 mmHg (10 W) and 101.4 ± 6.3 mmHg 
(20 W) for TAK mice; 106.7 ± 5.3 mmHg (10 W) and 
119.8 ± 5.8 mmHg (20 W) for WT mice; Fig. 1C).
Effects on urinary protein and serum creatinine
In the TAK mice, urinary protein excretion decreased 
from 2.51 ± 0.60 mg/day at 10 W to 1.48 ± 0.24 mg/day 
at 20 W.  In contrast, urinary protein excretion in the AK 
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group increased from 2.60 ± 0.66 mg/day (10 W) to 4.42 
± 1.09 mg/day (20 W).  Urinary protein excretion in the 
TAK mice at 20 weeks of age was significantly lower 
than that in the AK mice (Fig. 2A).  The level of protei-
nuria in the TAK mice was also lower than that in the 
WT mice [2.99 ± 0.13 mg/day (10 W), 2.92 ± 0.28 mg/
day (20 W)], but the difference was not significant.  We 
also examined the level of proteinuria in WT mice that 
had undergone uninephrectomy [n=4, 1.63 ± 0.27 mg/
day (10 W), 1.98 ± 0.28 mg/day (20 W)].  There were 
no significant differences in the levels of proteinuria 
between WT mice that had undergone uninephrectomy 
and TAK mice.  In the analysis of renal function, the 
serum creatinine level in the TAK mice increased less 
than in the AK mice, but it was not significantly lower 
in the TAK mice than in the AK mice at 20 W [0.36 ± 
0.07 mg/dl (10 W) and 0.50 ± 0.11 mg/dl (20 W) for AK 
mice; 0.34 ± 0.08 mg/dl (10 W) and 0.42 ± 0.14 mg/dl 
(20 W) for TAK mice; 0.35 ± 0.01 mg/dl (10 W) and 
0.36 ± 0.04 mg/dl (20 W) for WT mice; Fig. 2B].
Fig. 1. Serum glucose (A), body weight (B), and systolic blood pressure (C) in wild-type (WT), Mafa–/–Mafk+ (AK), and 
TCV-116-treated Mafa–/–Mafk+ (TAK) mice.  Open triangles, closed squares, and open circles indicate WT mice, 
AK mice, and TAK mice, respectively.  Each bar represents the mean ± SEM (*P<0.01, AK mice and TAK mice 
vs. WT mice).  W, weeks old.
Fig. 2. Urinary protein (A) and serum creatinine (B) in wild-type (WT), 
Mafa–/–Mafk+ (AK), and TCV-116-treated Mafa–/–Mafk+ (TAK) 
mice.  Open triangles, closed squares, and open circles indicate WT 
mice, AK mice, and TAK mice, respectively.  Closed triangles in-
dicate WT mice that had undergone uninephrectomy (uWT).  Each 
bar represents the mean ± SEM (#P<0.01, AK mice vs. TAK mice 
and uWT mice).  W, weeks old.
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Effect on renal size
The mean single kidney weight to body weight ratio 
of the WT mice was 0.67 ± 0.07%.  The kidney size of 
the AK mice was enlarged at 20 W (a ratio of 2.47 ± 
0.11%).  In contrast, the kidney weight to body weight 
ratio of the TAK mice at 20 W was 1.96 ± 0.11%, and it 
was significantly lower than that of the AK mice (Fig. 
3).
Histopathology
Next, we performed histological analysis of kidneys 
from 20-week-old AK, TAK, and WT mice.  Glomerular 
hypertrophy, mesangial matrix expansion, and nodular 
lesions were observed in PAS-stained kidney sections 
from AK mice (Fig. 4C and 4D).  However, mesangial 
matrix expansion was less obvious in the TAK mice (Fig. 
4E and 4F).  Furthermore, no nodular lesions were ob-
served in the TAK mice.  The mean glomerular surface 
area of the TAK mice was significantly smaller than that 
of the AK mice (5071.5 ± 176.8 µm2 for AK mice, 3855.8 
± 20.8 µm2 for TAK mice, 3064.2 ± 141.5 µm2 for WT 
mice; Fig. 5).  The MT-stained sections showed that the 
amount of fibrosis was less in the TAK mice than in the 
AK mice (Fig. 4G and 4H).
Effect of Urinary 8-OHdG
We also evaluated oxidative stress by measuring the 
urinary excretion of 8-OHdG, which is accepted as a 
sensitive marker for oxidative DNA damage in vivo.  In 
the AK mice, urinary excretion of 8-OHdG increased 
from 380.3 ± 104.1 ng/day at 10 W to 523.9 ± 72.7 ng/
day at 20 W.  In contrast, the urinary levels of 8-OHdG 
in the TAK group decreased from 378.6 ± 41.4 ng/day 
at 10 W to 189.0 ± 25.3 ng/day at 20 W (Fig. 6).
Discussion
A variety of mouse models provide valuable insight 
into the development of diabetic nephropathy [4].  They 
are also expected to serve as a useful platform for testing 
novel therapeutic strategies.  In general, diabetic neph-
ropathy in humans is a late complication of diabetes, 
occurring in susceptible patients after 10–20 years of 
diabetes [30].  Consequently, mouse models of diabetes 
need to be maintained for extended periods after the 
onset of hyperglycemia, usually 3–8 months, in order to 
detect diabetic nephropathy [30].  The major limitations 
in many mouse models are a lack of observed hyperten-
sion and the absence of advanced pathological lesions 
[4, 30].  Previously, we have reported that Mafa–/–Mafk+ 
mice that have not undergone uninephrectomy develop 
severe overt diabetes mellitus by 5 weeks old and show 
higher levels of proteinuria and serum creatinine at 10 
weeks old than WT mice [27].  Furthermore, AK mice, 
which have undergone uninephrectomy, demonstrate 
advanced pathological lesions of diabetic nephropathy 
within 20 weeks [27].  In this study, we tried to ascertain 
whether AK mice might also be a useful model for test-
ing drug of treatments for diabetic nephropathy.  In the 
present study, the progression of nephropathy in AK mice 
was significantly suppressed by treatment with TCV-116. 
The results suggested that AK mice are not only a good 
model of diabetic nephropathy but also might be a use-
ful tool for analysis of treatments for diabetic neph-
ropathy.
Both AK mice and TAK mice developed diabetes mel-
litus, and there were no significant differences between 
the two groups with respect to serum glucose levels and 
body weight during the observation period (Fig. 1A and 
1B).  Some studies have reported that TCV-116 might 
improve glucose levels [1, 25].  However, there were no 
significant differences in serum glucose levels between 
the AK and TAK mice.  In this study, we could not detect 
any beneficial effects of TCV-116 treatment on glucose 
Fig. 3. The ratio of kidney weight to body weight 
in wild-type, Mafa–/–Mafk+, and TCV-
116-treated Mafa–/–Mafk+ mice at 20 
weeks old (*P<0.01).
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Fig. 4. Histological appearance of kidney sections at 20 weeks old.  Wild-type (WT) mice (A, B), Mafa–/–Mafk+ (AK) mice (C, D, G), 
and TCV-116-treated Mafa–/–Mafk+ TAK mice (E, F, H).  Periodic acid-Schiff (PAS) (A, C, E, ×100; B, D, F, ×400) and Mas-
son’s trichrome (MT) (G, H, ×100) staining.  Glomerular hypertrophy, mesangial matrix expansion, and nodular lesions were 
observed in PAS-stained kidney sections from AK mice (C and D).  The arrowheads show nodular lesions.  In the MT-stained 
sections, the blue area, which shows fibrosis, was smaller in the TAK mice (H) than in the AK mice (G).  Scale bar, 100 µm.
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levels in TAK mice.  The mean blood pressure of the 
TAK mice, which were treated with TCV-116, was 
lower than that of the AK mice at 20 W, but the difference 
was not significant.  In contrast, the level of proteinuria 
in the TAK mice was significantly lower than that in the 
AK mice at 20 W.  In the present study, treatment with 
TCV-116 (5 µg/kg/day) was not sufficient to reduce 
blood pressure but did decrease proteinuria due to dia-
betic nephropathy effectively.  The level of protein in 
the urine of the WT mice did not change from 10 to 20 
weeks of age, and the proteinuria of the WT mice at 20 
W was higher than that of the TAK mice.  We also ex-
amined the levels of proteinuria in WT mice that had 
undergone uninephrectomy and found that the level of 
proteinuria was 1.63 ± 0.27 mg/day at 10 W and 1.98 ± 
0.28 mg/day at 20 W.  These results indicated that, in the 
TAK mice, the level of proteinuria was improved nearly 
to that of WT mice that had undergone uninephrectomy. 
The histological analysis showed that the AK mice de-
veloped severe diabetic nephropathy, with nodular le-
sions, mesangial matrix expansion, and fibrosis.  In 
contrast, the TAK mice did not show severe nephropathy 
(Fig. 4).  It is also known that kidney size may be en-
larged in diabetic nephropathy [18].  In the present study, 
the kidney size of the AK mice was enlarged (Fig. 3). 
Thus, the improvement of diabetic nephropathy in the 
TAK mice was also confirmed by the results of the his-
tological and kidney size analyses.
Treatments that inhibit RAS suppress the progress of 
diabetic nephropathy in both animal models and humans 
[3, 7, 24].  The RAS system regulates renal vasomotor 
activity, maintains optimal salt and water homeostasis, 
and modifies cellular proliferation in the nephron [3]. 
On the basis of the homeostatic effects of the RAS sys-
tem on the kidney, treatments that inhibit RAS have been 
reported to protect against glomerular capillary hyperten-
sion, proteinuria, and renal fibrosis [20, 29, 34].  In the 
current study, treatment of AK mice with the angiotensin 
II receptor blocker TCV-116 was effective in ameliorat-
ing proteinuria (Fig. 2), renal fibrosis (Fig. 4), and kidney 
enlargement (Fig. 3).
Diabetes introduces multiple sources of oxidative 
stress, and the stress factors appear early in the disease 
and worsen as the disease progresses [19, 33].  Increased 
oxidative stress in diabetes mellitus has been implicated 
in the pathogenesis of diabetic nephropathy [5, 8, 14]. 
Fig. 5. Histological analysis of glomerular surface 
area in wild-type (WT), Mafa–/–Mafk+ (AK), 
and TCV-116-treated Mafa–/–Mafk+ (TAK) 
mice.  The mean glomerular surface area of 
the AK group was significantly larger than 
those of the other groups.  After TCV-116 
treatment, the glomerular surface area was 
significantly decreased in the TAK group. 
Data are means ± SEM.  *P<0.01.
Fig. 6. Urinary 8-OHdG levels in wild-type (WT), 
Mafa–/–Mafk+ (AK), and TCV-116-treated 
Mafa–/–Mafk+ (TAK) mice.  Open triangles, 
closed squares, and open circles indicate WT 
mice, AK mice, and TAK mice, respectively. 
The urinary 8-OHdG level in the TAK mice 
was significantly decreased relative to that in 
the AK mice at 20 weeks old.  Data are means 
± SEM.  *P<0.01, AK mice and TAK mice 
vs. WT mice; **P<0.01, AK mice vs. TAK 
mice and WT mice; #P<0.05, TAK mice vs. 
WT mice.  W, weeks old.
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It is also known that angiotensin II in the kidney gener-
ates reactive oxygen species [3, 7].  TCV-116 has been 
reported to have antioxidant activity [6, 22], and 8-OHdG 
is known as a sensitive marker for oxidative DNA dam-
age in vivo.  In the current study, the urinary levels of 
8-OHdG in the AK and TAK mice were higher than those 
in the WT mice at 10 W.  Hyperglycemia induces oxida-
tive stress by various mechanisms [13, 33].  The higher 
urinary levels of 8-OHdG in the AK and TAK mice at 
10 W might be induced by hyperglycemia.  The AK and 
TAK mice displayed hyperglycemia at 20 W.  However, 
the urinary level of 8-OHdG in the TAK mice was sig-
nificantly lower than that of the AK mice at 20 W.  This 
result suggested that TCV-116 treatment was effective 
in decreasing oxidative stress in TAK mice.  It is also 
very interesting to consider the relationships of oxidative 
stress and RAS with MAFA and MAFK.  However, it is 
unknown whether MAFA and/or MAFK increases oxida-
tive stress or its effects on RAS.  Further studies to define 
these issues may clarify the mechanisms that are respon-
sible for the development of diabetic nephropathy.
In this study, we showed that, after uninephrectomy, 
Mafa–/–Mafk+ mice developed severe diabetic neph-
ropathy, which improved upon treatment with TCV-116. 
From these results, we concluded that the mouse model 
of diabetic nephropathy, namely Mafa–/–Mafk+ mice 
subjected to uninephrectomy, is a useful model for 
analysis of diabetic nephropathy and a useful tool for 
development of new drugs that target this disease.
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